Exploration of immune-related cells and ceRNA in squamous cell lung cancer

Wang, Lijun; Wang, Hao; Xu, Ke; Xu, Yehong; Wang, Yong; Song, Wei

doi:10.1097/md.0000000000027058

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7] lncRNAs competitively bind to miRNAs, to regulate the expression level of mRNAs and involve in the regulation of biological behaviors of tumor cells. [8–10] The ceRNA network plays a vital role in the development of various malignant tumors. [11–13] A large number of studies have shown that miRNA can guide RNA-induced silencing complex (RISC) to bind to target mRNA, leading to RNA degradation or translational inhibition.…”

Section: Introductionmentioning

confidence: 99%

The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal squamous cell carcinoma

Dong

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Laryngeal squamous cell carcinoma (LSCC) is one of the most common forms of head and neck cancers. However, few studies have focused on the correlation between competing endogenous RNA (ceRNAs) and immune cells in LSCC.Methods: RNAseq expression of LSCC and adjacent tissues were downloaded from The Cancer Genome Atlas to establish a ceRNA network. The key gene in ceRNA was screened by the cox regression analysis to establish a prognostic risk assessment model. The CIBERSORT algorithm was then used to screen important tumor-infiltrating cells related to LSCC. Finally, co-expression analysis was applied to explore the relationship between key genes in the ceRNA network and tumor-infiltrating cells. The external datasets were used to validate critical biomarkers.Results: We constructed a prognostic risk assessment model of key genes in the ceRNA network. As it turned out, Kaplan-Meier survival analysis showed significant differences in overall survival rates between high-risk and low-risk groups (P < .001). The survival rate of the high-risk group was drastically lower than that of the low-risk group, and the AUC of 1 year, 3 years, and 5 years were all above 0.7. In addition, some immune infiltrating cells were also found to be related to LSCC. In the co-expression analysis, there is a negative correlation between plasma cells and TUBB3 (r = −0.33, P = .0013). External dataset validation also supports this result. Conclusion:In this study, we found that some key genes (SLC35C1, CLDN23, HOXB7, STC2, TMEM158, TNFRSF4, TUBB3) and immune cells (plasma cells) may correspond to the prognosis of LSCC.Abbreviations: ceRNA = competing endogenous RNA, DElncRNAs = differentially expressed lncRNAs, DEmRNAs = differentially expressed mRNAs, GEO = Gene Expression Omnibus, GO = Gene Ontology, HNSCC = head and neck squamous cell carcinoma, KEGG = Kyoto Encyclopedia of Genes and Genomes, LSCC = laryngeal squamous cell carcinoma, OS = overall survival, TCGA = The Cancer Genome Atlas.

show abstract

Section: Introductionmentioning

confidence: 99%

The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal squamous cell carcinoma

Dong

et al. 2022

Medicine

View full text Add to dashboard Cite

show abstract

Long Noncoding RNA NKX2-1-AS1 Accelerates Non-Small Cell Lung Cancer Progression through the miR-589-5p/NME1 Axis

Chen,

Jiang,

Huang

et al. 2024

Cell Biochem Biophys

View full text Add to dashboard Cite

Significance of NKX2-1 as a biomarker for clinical prognosis, immune infiltration, and drug therapy in lung squamous cell carcinoma

Lin,

Wang,

Shi

et al. 2024

PeerJ

View full text Add to dashboard Cite

Background This study was performed to determine the biological processes in which NKX2-1 is involved and thus its role in the development of lung squamous cell carcinoma (LUSC) toward improving the prognosis and treatment of LUSC. Methods Raw RNA sequencing (RNA-seq) data of LUSC from The Cancer Genome Atlas (TCGA) were used in bioinformatics analysis to characterize NKX2-1 expression levels in tumor and normal tissues. Survival analysis of Kaplan–Meier curve, the time-dependent receiver operating characteristic (ROC) curve, and a nomogram were used to analyze the prognosis value of NKX2-1 for LUSC in terms of overall survival (OS) and progression-free survival (PFS). Then, differentially expressed genes (DEGs) were identified, and Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and Gene Set Enrichment Analysis (GSEA) were used to clarify the biological mechanisms potentially involved in the development of LUSC. Moreover, the correlation between the NKX2-1 expression level and tumor mutation burden (TMB), tumor microenvironment (TME), and immune cell infiltration revealed that NKX2-1 participates in the development of LUSC. Finally, we studied the effects of NKX2-1 on drug therapy. To validate the protein and gene expression levels of NKX2-1 in LUSC, we employed immunohistochemistry(IHC) datasets, The Gene Expression Omnibus (GEO) database, and qRT-PCR analysis. Results NKX2-1 expression levels were significantly lower in LUSC than in normal lung tissue. It significantly differed in gender, stage and N classification. The survival analysis revealed that high expression of NKX2-1 had shorter OS and PFS in LUSC. The multivariate Cox regression hazard model showed the NKX2-1 expression as an independent prognostic factor. Then, the nomogram predicted LUSC prognosis. There are 51 upregulated DEGs and 49 downregulated DEGs in the NKX2-1 high-level groups. GO, KEGG and GSEA analysis revealed that DEGs were enriched in cell cycle and DNA replication.The TME results show that NKX2-1 expression was positively associated with mast cells resting, neutrophils, monocytes, T cells CD4 memory resting, and M2 macrophages but negatively associated with M1 macrophages. The TMB correlated negatively with NKX2-1 expression. The pharmacotherapy had great sensitivity in the NKX2-1 low-level group, the immunotherapy is no significant difference in the NKX2-1 low-level and high-level groups. The analysis of GEO data demonstrated concurrence with TCGA results. IHC revealed NKX2-1 protein expression in tumor tissues of both LUAD and LUSC. Meanwhile qRT-PCR analysis indicated a significantly lower NKX2-1 expression level in LUSC compared to LUAD. These qRT-PCR findings were consistent with co-expression analysis of NKX2-1. Conclusion We conclude that NKX2-1 is a potential biomarker for prognosis and treatment LUSC. A new insights of NKX2-1 in LUSC is still needed further research.

show abstract

Exploration of immune-related cells and ceRNA in squamous cell lung cancer

Cited by 3 publications

References 39 publications

The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal squamous cell carcinoma

The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal squamous cell carcinoma

Long Noncoding RNA NKX2-1-AS1 Accelerates Non-Small Cell Lung Cancer Progression through the miR-589-5p/NME1 Axis

Significance of NKX2-1 as a biomarker for clinical prognosis, immune infiltration, and drug therapy in lung squamous cell carcinoma

Contact Info

Product

Resources

About